Evidence map›Paper›PMID 34617306›Full record

ArticleAnnals of neurology2021

Tau-Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease.

Sandhitsu R Das, Xueying Lyu, Michael Tran Duong, Long Xie, Lauren McCollum, Robin de Flores, Michael DiCalogero, David J Irwin, Bradford C Dickerson, Ilya M Nasrallah and 3 more

Abstract read
In one paragraph

Article in Annals of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Clinical criteria for limbic-predominant age-related TDP-43 encephalopathy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. A novel eye-tracking digital marker outperforms plasma biomarkers in detecting cognitive impairment.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Spectral normative modeling of brain structure.medRxiv : the preprint server for health sciences · 2025
    Article
  17. The Consortium for Clarity in ADRD Research Through Imaging (CLARiTI).Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  18. Article
  19. Article
  20. Tau-neurodegeneration mismatch reveals vulnerability and resilience to comorbidities in Alzheimer's continuum.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sandhitsu R DasDepartment of Neurology, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0003-0530-2887
Xueying LyuDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.
Michael Tran DuongDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.
Long XieDepartment of Radiology, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-7184-7028
Lauren McCollumDepartment of Medicine, University of Tennessee, Knoxville, TN, USA.
Robin de FloresUniversité de Caen Normandie, INSERM UMRS U1237, Caen, France.
Michael DiCalogeroDepartment of Neurology, University of Pennsylvania, Philadelphia, PA, USA.
David J IrwinDepartment of Neurology, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-5599-5098
Bradford C DickersonMassachusetts General Hospital, Boston, MA, USA.
Ilya M NasrallahDepartment of Radiology, University of Pennsylvania, Philadelphia, PA, USA.
Paul A YushkevichDepartment of Radiology, University of Pennsylvania, Philadelphia, PA, USA.
David A WolkDepartment of Neurology, University of Pennsylvania, Philadelphia, PA, USA.
Alzheimer's Disease Neuroimaging Initiative

Funding

Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI Duygu Tosun-Turgut · 2016 to 2026
$226.7M
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI STEVEN E ARNOLD · 2019 to 2026
$36.5M
UPenn ADCC Biomarker CoreP30AG010124 · NIA · UNIVERSITY OF PENNSYLVANIA · PI DETRE, JOHN A · 1991 to 2020
$35.1M
Research Education ComponentP30AG072979 · NIA · UNIVERSITY OF PENNSYLVANIA · PI DAVID A WOLK · 2021 to 2026
$24.8M
Understanding Environmental Contributions to Heterogeneity in bvFTD.P01AG066597 · NIA · UNIVERSITY OF PENNSYLVANIA · PI David John Irwin, Corey T McMillan · 2020 to 2026
$18.8M
Multicultural Community Dementia ScreeningR01AG071514 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GALVIN, JAMES E · 2021 to 2025
$13.8M
Spreading Tau Pathology in Non-Amnestic Alzheimer's DiseaseR01AG054519 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jeffrey S Phillips · 2018 to 2026
$7.4M
Ex Vivo Imaging of the Aging Brain to Discover Morphology/Pathology AssociationsR01AG056014 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Paul A. Yushkevich · 2017 to 2026
$4.5M
Microscopic and Large-Scale Networks of Molecular Pathology in Frontotemporal Lobar DegenerationR01NS109260 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI IRWIN, DAVID JOHN · 2019 to 2023
$3.8M
Modulators of Medial Temporal Lobe Subregion Structure and Function in Normal and Pathological AgingR01AG055005 · NIA · UNIVERSITY OF PENNSYLVANIA · PI WOLK, DAVID A · 2017 to 2021
$3.3M
Improving Transition Outcomes through Accessible Health IT and Caregiver SupportR01AG039474 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PIETTE, JOHN D. · 2011 to 2015
$2.7M
NIA NIH HHS P01 AG066597NIA NIH HHS P30 AG010124NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG072979NIA NIH HHS R01 AG039474NIA NIH HHS R01 AG054519NIA NIH HHS R01 AG055005NIA NIH HHS R01 AG056014NIA NIH HHS R01 AG071514NIA NIH HHS RF1 AG069474NIA NIH HHS U01 AG024904NIA NIH HHS U19 AG024904NIBIB NIH HHSNIH HHS R01-AG-054435-02NIH HHS R01-AG-056014-04NINDS NIH HHS R01 NS109260
6 · The paper itself

Abstract

objectiveTau neurofibrillary tangles (T) are the primary driver of downstream neurodegeneration (N) and subsequent cognitive impairment in Alzheimer's disease (AD). However, there is substantial variability in the T-N relationship - manifested in higher or lower atrophy than expected for level of tau in a given brain region. The goal of this study was to determine if region-based quantitation of this variability allows for identification of underlying modulatory factors, including polypathology.

methodsCortical thickness (N) and

resultsThe summary T-N mismatch metric correlated with underlying factors such as age and burden of white matter hyperintensity lesions. Data-driven subgroups based on clustering of residuals appear to represent different biologically relevant phenotypes, with groups showing distinct spatial patterns of higher or lower atrophy than expected.

interpretationThese data support the notion that a measure of deviation from a normative relationship between tau burden and neurodegeneration across brain regions in individuals on the AD continuum captures variability due to multiple underlying factors, and can reveal phenotypes, which if validated, may help identify possible contributors to neurodegeneration in addition to tau, which may ultimately be useful for cohort selection in clinical trials. ANN NEUROL 2021;90:751-762.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesAtrophyCognitive DysfunctionHumansMaleNeurofibrillary TanglesPhenotypetau ProteinsAmyloid beta-Peptidestau Proteins

Identifiers

PMID34617306
PMCPMC8841129

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.